BRIEF-Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by US FDA for the Treatment of Alzheimer’s Disease and Dementia
Reuters
Nov 05, 2025
BRIEF-Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by US FDA for the Treatment of Alzheimer’s Disease and Dementia
Nov 5 (Reuters) - Nexalin Technology Inc NXL.O:
NEXALIN TECHNOLOGY’S Q-SUBMISSION FOR GEN-2 SYNC ACCEPTED BY U.S. FDA FOR THE TREATMENT OF ALZHEIMER’S DISEASE AND DEMENTIA
Source text: ID:nGNE7C10jV
Further company coverage: NXL.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.